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Graft rejection in transplant patients is managed clinically by suppressing T-cell function with
immunosuppressive drugs such as prednisolone and methylprednisolone. In such
immunocompromised hosts, human cytomegalovirus (HCMV) is an important opportunistic
pathogen and can cause severe morbidity and mortality. Currently, the effect of
glucocorticosteroids (GCSs) on the HCMV life cycle remains unclear. Previous reports showed
enhanced lytic replication of HCMV in vitro in the presence of GCSs. In the present study, we
explored the implications of steroid exposure on latency and reactivation. We observed a direct
effect of several GCSs used in the clinic on the activation of a quiescent viral major immediate-
early promoter in stably transfected THP-1 monocytic cells. This activation was prevented by the
glucocorticoid receptor (GR) antagonist Ru486 and by shRNA-mediated knockdown of the GR.
Consistent with this observation, prednisolone treatment of latently infected primary monocytes
resulted in HCMV reactivation. Analysis of the phenotype of these cells showed that treatment
with GCSs was correlated with differentiation to an anti-inflammatory macrophage-like cell type.
On the basis that these observations may be pertinent to HCMV reactivation in post-transplant
settings, we retrospectively evaluated the incidence, viral kinetics and viral load of HCMV in liver
transplant patients in the presence or absence of GCS treatment. We observed that combination
therapy of baseline prednisolone and augmented methylprednisolone, upon organ rejection,
significantly increased the incidence of HCMV infection in the intermediate risk group where
donor and recipient are both HCMV seropositive (D+R+) to levels comparable with the high risk
D+R” group.
INTRODUCTION
Human cytomegalovirus (HCMV) is a member of the
Betaherpesvirinae subfamily, which primarily causes mor-
bidity and mortality in neonates or in HIV and transplant
patients (Bristow et al., 2011; Husain et al., 2009).
HCMV displays a lytic and a latent phase depending on the
infected cell type and the differentiation status of the cell
(Bolovan-Fritts et al., 1999; Goodrum et al., 2002; Hahn et al.,
1998; Huang et al., 2012; Mendelson et al., 1996; Reeves et al.,
2005b; Sindre et al., 1996; So¨derberg-Naucle´r et al., 1997,
2001; Taylor-Wiedeman et al., 1994; Zhuravskaya et al.,
1997). HCMV gene expression is driven by the major
immediate-early promoter (MIEP), which is controlled by
binding of transcription factors to cis-regulatory regions3Deceased.
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including the enhancer (Cherrington & Mocarski, 1989;
Cherrington et al., 1991; Lang & Stamminger, 1993; Macias
& Stinski, 1993). During lytic infection, the MIEP is active
and the expression of the full array of viral genes results in
the production of new virions (Arrode & Davrinche, 2003;
Bayer et al., 2013; DuRose et al., 2012; O’Connor & Shenk,
2012; Sinzger et al., 1999a). Latency is established primarily
in monocytes and CD34+ progenitor cells, although other
sites may exist, (Sissons et al., 2002; Springer & Weinberg,
2004) in which the MIEP is suppressed resulting in a limited
set of transcripts and the lack of viral progeny (Bego et al.,
2005, 2011; Goodrum et al., 2007; Jenkins et al., 2004, 2008;
Montag et al., 2011; Reeves, 2011). Differentiation of latently
infected cells to dendritic cells (DC) results in de-repression
of the MIEP and initiation of the lytic cycle and the release of
infectious virus (Reeves et al., 2005a, b, c; Stenberg et al.,
1985; Stinski et al., 1983; Wathen & Stinski, 1982).
Currently, HCMV remains an important complication after
solid organ transplantation (SOT) despite the pre-emptive or
prophylactic use of valganciclovir (Kotton et al., 2013).
Symptoms vary but may culminate in organ loss (Boeckh &
Nichols, 2004; Crough & Khanna, 2009; Limaye et al., 2006).
In SOT, the serostatus of the donor is the most important risk
factor to develop HCMV-related disease, especially if the
recipient is seronegative (D+R2) (Humar & Snydman,
2009). The initial lack of HCMV-specific immune responses,
combined with a suppressed immune response of the recipient
may lead to productive HCMV infection of a variety of cell
types in the recipient (Arrode & Davrinche, 2003; Bayer et al.,
2013; DuRose et al., 2012; O’Connor & Shenk, 2012; Sinzger
et al., 1999a). Consequently, the D+R2 group is considered a
high-risk group. An intermediate risk is found when both the
donor and recipient are seropositive (D+R+) and a lower
risk in a D2R+ setting where reactivation of latent virus in
the recipient in the face of pre-existing immunity occurs.
Finally, the lowest risk is when both donor and recipient are
HCMV seronegative (Atabani et al., 2012).
The risks for HCMV-related complications post-transplant
are often attributed to T-cell suppression by immunosup-
pressive drugs such as prednisolone or methylpredniso-
lone, both glucocorticosteroids (GCSs), which are used
post-transplant in baseline therapies and/or in cases of
acute rejection (i.e. augmented therapy) (Bunde et al.,
2005; Cope et al., 1997; Cwynarski et al., 2001; Gamadia
et al., 2003; Gratama et al., 2001; Hebart et al., 2002; Krause
et al., 1997; Ljungman et al., 2011; Nebbia et al., 2007;
Ozdemir et al., 2002; Reusser et al., 1991, 1999). The
mechanism of action of GCSs is currently not completely
understood. GCSs act via the glucocorticoid receptor
(GR), which is a ligand-regulated transcription factor
(Buckingham, 2006; Pratt et al., 2006; van der Velden,
1998). In the absence of a ligand, the steroid-binding
domain of the GR is bound by inhibiting chaperone
proteins. Upon GCS binding, GR undergoes a conforma-
tional change, releases the chaperones, translocates to the
nucleus and binds to a 15 bp glucocorticoid response
element (GRE) resulting in transcriptional activation
(Buckingham, 2006; Pratt et al., 2006; van der Velden,
1998). However, other mechanisms of GCS that do not
involve GR binding to a GRE have been described, these
are involved in cytokine production and T-cell inhibition
(Almawi et al., 1999; Buckingham, 2006; Paliogianni et al.,
1993; Pratt et al., 2006; van der Velden, 1998).
It has also been reported that GCSs have a direct enhancing
effect, in vitro, on HCMV lytic infection in fibroblasts (St
George & Rinaldo, 1994; Tanaka et al., 1984; West et al.,
1988) and macrophages (Lathey & Spector, 1991) although
one report contradicts these observations (Scott et al.,
2000). In contrast, no data are available on the impact of
GCSs on reactivation of HCMV from latency. Conse-
quently, we set out to explore the effects of GCSs on
reactivation of HCMV from latency. We show that GCSs
can activate the MIEP in a GR-dependent pathway and
that, through this mechanism prednisolone is able to
reactivate latent HCMV from primary monocytes. To
investigate the clinical relevance of these findings, we
performed a retrospective analysis of a liver transplant
population to assess the effect of baseline prednisolone and
augmented methylprednisolone in case of acute graft
rejection on the incidence, viral kinetics and viral load of
HCMV. In case of HCMV reactivation, the peak viral load
remains similar between all treatment groups. Treatment
with both baseline prednisolone and augmented methyl-
prednisolone significantly increased the incidence of
HCMV infection in the D+R+ group where donor and
recipient are both HCMV seropositive. Taken together,
these data suggest that GCSs play a role in the viral kinetics
of latency and reactivation and that treatment with these
compounds may increase the probability of HCMV-related
complications post-transplantation.
RESULTS
GCSs activate the MIEP in a THP-1-MIEP-EGFP
reporter assay
We first assessed the influence of GCSs on the activation of
the MIEP. In stably transfected THP-1-MIEP-EGFP cells,
the MIEP was epigenetically silenced, but was activated
upon differentiation of cells by phorbol 12-myristate 13-
acetate (PMA; see Table 1). In this robust assay [Z9 of 0.91
(Zhang et al., 1999)], 17 clinically used GCSs and several
reference compounds i.e. pam3cys, PMA, ionomycin,
SAHA and polyinosinic-polycytidylic acid (Poly I:C) were
investigated (Table 1).
All the selected GCSs, as well as reference compounds PMA,
SAHA, pam3cys and ionomycin, activated the MIEP whereas
Poly I:C did not have any effect. Although SAHA, PMA,
ionomycin and pam3cys induced a higher maximal response
compared to the GCSs, the GCS-induced increase in MIEP
activity was reproducible in 3 independent replicates and over
a broad range of lowest effective concentrations (LECs)
ranging from nM to fM concentrations.
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GCSs activate the MIEP in a GR-dependent
manner in THP-1-MIEP-EGFP cells
To determine if prednisolone and methylprednisolone
activate the MIEP via the GR, THP-1-MIEP-EGFP cells
were treated with prednisolone or methylprednisolone in the
presence or absence of the GR inhibitor Ru486 (Cadepond
et al., 1997). Treatment with prednisolone or methylpredni-
solone activated the MIEP resulting in increased levels of
EGFP expression as determined by mean fluorescent inten-
sity (MFI) of the cell population (Fig. 1a, b). Concentrations
of methylprednisolone below 1022 mM did not have any
effect and only baseline fluorescence was observed. When GR
inhibitor Ru486 was added simultaneously with predniso-
lone or methylprednisolone, the MIEP could no longer be
activated (Fig. 2a, b) suggesting that the GR pathway is
followed.
The involvement of GR in GCS-mediated MIEP activation
was further demonstrated using THP-1-MIEP-EGFP cells
transfected with the empty vector or with shRNAs against
the GR, LacZ-D12 and Luc-G7. Analysis using reverse
transcriptase quantitative PCR (RT-qPCR) showed that
shRNA NR3C1_1, shRNA NR3C1_2, shRNA NR3C1_3 and
shRNA NR3C1_4, respectively, knocked down 53.1, 58.5,
17.1 and 29.1% of the GR expression. None of the negative
control shRNAs against LacZ-D12 and Luc-G7 resulted in
any knockdown of the GR. Subsequent to shRNA transfec-
tion, the cells were treated with 160 nM prednisolone or
1 mM PMA. None of the three negative controls had any
effect on PMA or prednisolone-induced MIEP activation. In
addition, besides an off-target effect of shRNA NR2C1_2,
none of the other GR-specific shRNAs had any effect on
MIEP activation with PMA. However, all four shRNAs
against GR significantly downregulated the activation of the
MIEP after treatment with prednisolone (Fig. 1c).
The activation of the MIEP by methylprednisolone was
inhibited by treatment with Ru486 and shRNA knockdown
of the GR, strongly suggesting that the MIEP is activated
through a GR-mediated mechanism by prednisolone and
methylprednisolone.
Prednisolone reactivates HCMV in primary
monocytes
To investigate whether GCSs can mediate reactivation of
HCMV from latently infected cells, primary CD14+
monocytes were latently infected with wild-type TB40/E
or TB40/E-IE2-YFP in vitro and subsequently treated with
400 nM prednisolone or differentiated to immature or
mature monocyte-derived DCs (iDC and mDC, respect-
ively). Activation of immediate-early (IE) expression was
measured by manual counting of IE expressing cells after
96 h (Fig. 2). Despite some variability between donors in
the number of IE expressing cells, as reported before
(Huang et al., 1996), differentiation to iDCs and mDCs
increased the number of IE expressing cells (P50.001 and
P,0.0001, respectively). Interestingly, also treatment with
prednisolone reproducibly increased IE expression in latently
infected monocytes (P,0.0001) (Fig. 2a). Although activa-
tion of the MIEP is a first step to initiation of the lytic cycle,
Table 1. LEC (mM) and maximal response (MaxResp, % increase) of commonly used glucocorticosteroids and reference compounds
on MIEP-driven EGFP expression in THP-1 cells (n53)
Drug name LEC (mM) MaxResp (% increase)
Beclometasone dipropionate 0.000060±0.000019 151±37
Budesonide ,0.000039±0.000002 186±34
Dexamethasone 0.000156±0.000036 182±40
Hydrocortisone acetate 0.006167±0.003350 126±35
Methylprednisolone 0.000219±0.000011 159±33
Naflocort ,0.000038±0 196±38
Prednisolone 0.002343±0.000626 151±23
Betamethasone valerate ,0.000038±0 180±29
Desonide 0.000268±0.000105 165±38
Prednisolone acetate 0.003115±0.000485 161±25
Triamcinolone 0.002447±0.003009 125±26
Fluocinolone acetonide 0.000117±0.000076 168±19
Clocortolone pivalate 0.000278±0.000201 138±22
Difluprednate 0.000063±0.000007 153±38
Halcinonide ,0.000038±0 174±18
Alclometasone dipropionate 0.000188±0.000095 148±48
Fluocinonide 0.000138±0.000087 150±29
SAHA 2.070000±0.300000 261±82
Pam3cys 0.000640±0 767±111
PMA 0.000010±0 737±104
Ionomycin 0.082400±0.002200 717±95
Poly I:C Not active Not active
Glucocorticosteroids trigger reactivation of HCMV
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reactivation of virus from latency necessarily requires the
production of infectious virus. Therefore, the supernatant of
prednisolone treated and untreated latent monocytes was
transferred to fibroblasts and incubated until infectious centres
could be observed. Treatment with prednisolone resulted in
the production of infectious virus whereas supernatants from
untreated, latently infected monocytes did not (Fig. 2b).
In THP-1 cells, prednisolone activated the MIEP in a dose-
dependent manner via the GR. Similarly, we tested reacti-
vation in the presence of the GR inhibitor Ru486 (Fig. 2c) in
CD14+monocytes. Ru486 treatment had no effect on levels
of IE expression in latently infected untreated CD14+
monocytes. As expected, treatment of latently infected cells
with prednisolone significantly increased the number of IE
expressing cells (P50.001). We also showed that Ru486
leads to a decrease in number of IE expressing cells when
added to prednisolone treated cells (interaction in mixed
model, P50.007). This observation strongly suggests that
prednisolone activates the HCMV MIEP via a GR-mediated
pathway. While the best described mechanism of GCS-
induced cellular events is through GR binding to a GRE
consensus site, we did not detect any reproducible
interaction between the MIEP and the GR despite re-
peated chromatin immunoprecipitation (ChIP) experiments
(data not shown). Alternatively, prednisolone may trigger
MIEP activation by inducing differentiation of monocytes to
terminally differentiated macrophages or DCs. Conse-
quently, we tested if prednisolone changed the differenti-
ation state of monocytes (Fig. 3). Using a cluster of
differentiation markers specific for monocytes [CD14+/
CD1632/lo/DCsign2/CD80+ upon lipopolysaccharide (LPS)
activation], type 1 macrophages (CD14+/CD1632/DCsignlo/
CD80+ upon LPS activation), type 2 macrophages (CD14+/
CD163+/DCsignlo/CD80lo upon LPS activation) and dend-
ritic cells (CD142/CD1632/DCsignhigh/CD80+ upon LPS
activation), we showed that prednisolone treatment did
not result in differentiation of monocytes to DCs or type 1
macrophages, but did increase markers of type 2 macro-
phages (e.g. CD163, absent response in CD80 to LPS).
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Fig. 1. GR-dependent MIEP activation by prednisolone and methylprednisolone. THP-1-MIEP-EGFP cells treated with
prednisolone (a) or methylprednisolone (b) in the presence or absence of 5 mM Ru486. Activity of the MIEP was plotted as MFI
24 h post treatment (n56). The baseline MFI in untreated cells (horizontal full line) and the baseline MFI plus and minus three
times the SD (dotted lines) are indicated. Significance was determined using a two-tailed Student’s t-test (*P,0.01;
**P,0.001). (c) THP-1-MIEP-EGFP cells transfected with shRNA against GR (shRNA NR3C1_1–NR3C1_4), LacZ-D12 and
Luc-G7 or empty vector. Cells were treated with 160 nM prednisolone or 1 mM PMA (n53). Significant decreases in MIEP
activation were calculated using a two-tailed Student’s t-test (**P,0.001).
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Taken together, these data suggest that prednisolone
can reactivate HCMV from monocytes resulting in the
production of viral progeny. The mechanism via which
prednisolone activates the HCMV MIEP, and likely
subsequent reactivation, appears to be GR-driven, how-
ever, it is unlikely to proceed via binding of the GR to the
MIEP and probably occurs via an alternative pathway. In
addition, prednisolone leads to the induction of a subset of
macrophage type 2-like cell type markers suggesting a
novel differentiation-induced mechanism for HCMV
reactivation by GCSs.
The use of GCSs increases the risk for HCMV
infection in the D+R+ group of liver transplant
recipients.
In order to mirror the in vitro experiments, we
investigated the in vivo effects of steroids on the incidence
of HCMV infection, the viral load and the timing of
infection in liver transplant recipients in the context of the
HCMV serostatus of donor and recipient. Patients were
divided into four categories depending on the receipt of
prednisolone for baseline immunosuppression and/or
methylprednisolone for augmented immunosuppression.
There were no statistically significant differences in the
incidence of HCMV DNAemia in any of the steroid
subgroups or in the peak or cumulative HCMV loads in
patients within the subset of viraemic patients based on
receipt of steroids as baseline or augmented immuno-
suppression (Table 2). Viral loads were highest in the
patients receiving no steroids, but were comparable in
the other three groups. In the context of the timing of
the occurrence of HCMV DNAemia (defined as a VL in
whole blood .200 genomes ml21) patients who received
augmented steroid immunosuppression, irrespective of
whether they had baseline prednisolone, had a shorter
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Fig. 2. Reactivation of latent HCMV from primary CD14+ monocytes by prednisolone. Latently infected (TB40/E or TB40/E-
IE2-YFP) CD14+ monocytes were treated for 96 h with prednisolone or differentiated to iDCs or mDCs. IE positive cells were
manually counted and plotted. (a) Activation of the MIEP in CD14+ monocytes by treatment with 400 nM prednisolone or by
differentiation to monocyte-derived iDC and mDC (seven independently processed donors). P values were calculated by a
mixed model corrected for donor dependency (**P,0.0001; *P50.001). (b) Treatment of CD14+ monocytes with prednisolone
results in the production of infectious virus (n53, three independently processed donors, two technical replicates per donor). (c)
Inhibition of activation of the MIEP by Ru486. Latently infected (TB40/E-IE2-YFP) monocytes were left untreated or were treated
with 5 mM Ru486, 400 nM prednisolone or the combination of both for 96 h before IE expressing cells were counted manually
(five independently processed donors). Using a mixed model corrected for donor dependency, the P value was calculated
(*P50.001). On all boxplots, values outside tenth and ninetieth percentiles were considered outliers ($).
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time to DNAemia (21.5 days) compared to the other two
groups (no steroid treatment or prednisolone mainten-
ance only) (P50.05; Table 2).
Further, we investigated the incidence of DNAemia in
different donor-recipient groups according to steroid use.
As published previously, the highest risk for HCMV-related
complications was when a seropositive organ is introduced
in a seronegative recipient (D+R2) (Humar & Snydman,
2009). The lowest chance of developing HCMV disease was
when the recipient was seropositive for HCMV but faced
reactivation of HCMV that was present already in the
body upon immunosuppression (D2R+) (Fig. 4a). In the
D+R2 group of liver transplant recipients, the inci-
dence of DNAemia was very high (.90%) and therefore
the impact of baseline and augmented steroid use on
virological parameters was difficult to assess and no signi-
ficant differences were observed (Fig. 4, Table 3). However,
in the D+R+ and D2R+ groups the lower incidence of
DNAemia provides an opportunity to assess the impact of
steroid use on the incidence of HCMV DNAemia. In the
D2R+ group, DNAemia rates were comparable between
patients who received no steroids and those receiving main-
tenance steroids and augmented steroids. Patients who
received steroids in both clinical settings showed a non-
significant increase in the incidence of HCMV DNAemia.
The difference in DNAemia between the group with
maintenance steroids and maintenance plus augmented
steroids was of borderline significance (P50.07). In
contrast, in the D+R+ group the incidence of HCMV
DNAemia in patients receiving both baseline steroids and
augmented steroids compared to the other groups was
more pronounced. Statistically significant increases in the
incidence of HCMV DNAemia in the steroid -treated
patients (baseline and augmented) were observed com-
pared to all other groups (as individual comparisons;
Fig. 4, Table 3).
Under the influence of GCSs, the D+R+ group had an
increased risk of developing HCMV DNAemia shifting
them from an intermediate risk group to a high risk group,
which is comparable to the D+R2 group.
DISCUSSION
HCMV-related illness is an important risk factor post-
transplant and an increased incidence of HCMV in
transplant settings has been associated with GCS treatment
(Cope et al., 1997; Nebbia et al., 2007). Nevertheless, the
effects of GCSs on the virus itself have not been fully
investigated, especially the influence of GCSs on latency
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Table 2. Effects of different combinations of baseline maintenance steroid immunosuppression and augmented steroid
immunosuppression. Given are the days to DNAemia and peak HCMV load in blood. Statistically significant values are indicated (*)
Maintenance
prednisolone (Yes/No)
Augmented methylprednisolone
(Yes/No)
Incidence of DNAemia
(no. with DNAemia/
total in group)
Peak HCMV load
[mean of log10
genomes ml”1 (range)]
Days to DNAemia
[mean no. of days
(range)]
No No 24/92 3.47 (2.39–5.08) 25 (1–56)
Yes No 17/73 3.38 (2.36–5.12) 29 (1–57)
No Yes 21/72 2.96 (2.40–4.75) 23 (5–85)
Yes Yes 23/64 3.49 (2.58–4.91) 21* (1–53)
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and reactivation. As de-repression of the MIEP is a crucial
step in the switch between lytic and latent infection (Ghazal
et al., 1990; Lubon et al., 1989; Reeves, 2011; Sinclair,
2010), we used a THP-1-MIEP-EGFP reporter assay to
assess the MIEP activating potential of GCSs. THP-1 cells
have been used previously to study latency and reactivation
of HCMV and, consistent with the known silencing of the
MIEP in these cells after infection, MIEP-driven EGFP
expression was suppressed in the absence of a stimulus
(Ioudinkova et al., 2006; Keyes et al., 2012). However,
treatment of the THP-1-MIEP-EGFP cells with 17 clinically
relevant GCSs, as well as several reference compounds
known to activate the MIEP (SAHA, ionomycin and PMA)
(Groves et al., 2009; Phillips et al., 2005; Weinshenker et al.,
1988); to induce transcription factors, such as NFkB and
AP-1, associated with MIEP activation (Pam3cys) (Parker
et al., 2004; Pevsner-Fischer et al., 2007; Reeves, 2011)
or compounds known to reactivate other latent viruses
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according to GCS use. (a) Overview of the three risk groups for HCMV-related complications (untreated). The different
subgroups i.e. D+R+ (b), D+R” (c) and D”R+ (d) were evaluated under different immune-suppressive regimens. 0.0,
Regimen not based on steroids; 0.1, baseline therapy non-steroid plus augmented methylprednisolone treatment; 1.0, baseline
prednisolone treatment; 1.1, baseline prednisolone treatment plus augmented methylprednisolone treatment.
Table 3. Incidence of HCMV DNAemia in the different D/R serogroups for HCMV based on maintenance and augmented steroid use
Maintenance/augmented steroids (15Yes, 05No) D+R” (n530) D”R+ (n5110) D+R+ (n5104)
0.0 10/11 12/35 15/28
0.1 5/5 13/30 11/22
1.0 6/6 6/24 15/30
1.1 8/9 11/21 22/24*
*Significantly different to the 0.0 group (P50.005), the 1.0 group (P50.001) and the 0.1 group (P50.003).
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(SAHA) or HCMV (PMA) (Archin et al., 2012; Keyes et al.,
2012) resulted in the activation of the MIEP. Despite the
presence of Toll-like receptor 3 in THP-1 cells, immune-
regulator Poly I:C did not activate the MIEP (Alexopoulou
et al., 2001; Kumar et al., 2006).
The major pathway through which GCSs exert their effect
is the GR pathway. In fact, treatment with small molecule
GR inhibitor Ru486 (Cadepond et al., 1997) or shRNA-
mediated knock-down of GR completely abolished activa-
tion of the MIEP by prednisolone or methylprednisolone.
In contrast, neither Ru486 nor shRNA against GR had any
effect on PMA-mediated activation of the MIEP, this
suggests the involvement of the GR pathway in GCS-
mediated MIEP activation.
In addition, a CD14+ monocyte latency model was used to
investigate if GCSs could activate the MIEP and induce full
reactivation of latent virus. In untreated infected CD14+
monocytes, a small number of IE expressing cells were
observed, but there was no evidence of full reactivation of
virus in these cells. Similar observations have been made in
models of MCMV latency (Kurz et al., 1999), and we think
it is likely that in some monocytes IE gene expression
occurs sporadically but without progression to productive
infection. This is consistent with the view that, whilst IE1
gene expression is essential for initiation of reactivation
of virus, it may not always be sufficient, and other
checkpoints have to be passed before full reactivation
leading to infectious virus release occurs. In contrast,
treatment with prednisolone resulted in a GR-dependent
reactivation of IE gene expression and the production of
infectious virus. Although robust, this reactivation of
infectious virus was at low levels, which is consistent with
mouse models of reactivation from latency which have
also shown that only a few IE1 transcription reactivation
events appear to result in productive reactivation (Kurz &
Reddehase, 1999). Interestingly, treatment with GCSs
induces an anti-inflammatory state in monocytes and
macrophages (Joyce et al., 1997) and hydrocortisone
treatment of monocytes induces an anti-inflammatory
cell type resembling a type 2 macrophage (Ehrchen et al.,
2007), which are known to be permissive for HCMV
infection in vitro (Bayer et al., 2013). Our data show that,
unlike hydrocortisone which appears to only induce IE
expression in natural latent monocytes (Taylor-Wiedeman
et al., 1994), prednisolone is capable of fully reactivating
latent HCMV in experimentally latent monocytes and this
is likely due to the ability of prednisolone to induce a
strongly anti-inflammatory macrophage type 2-like cell
phenotype. Repeated attempts to detect binding of the GR
to the MIEP by ChIP in myeloid cells have not, so far, been
successful, perhaps suggesting an indirect mechanism. It is
worth emphasizing that GCSs have also been shown to
regulate gene expression via other mechanisms, for instance
via modulation of mRNA stability or via protein–protein
interactions (Buckingham, 2006; Pratt et al., 2006; van der
Velden, 1998).
It is well established that HCMV contributes to post-
transplant morbidity; HCMV may cause damage to the
transplanted organ, increases the risk for graft rejection and
may cause HCMV syndrome (Crough & Khanna, 2009;
Ljungman et al., 2011; Volpin et al., 2002). To address
whether our in vitro findings had implications in vivo, we
retrospectively investigated a cohort of liver transplant
patients who had received GCSs as immune-suppressants.
In the overall patient population, we detected an earlier
onset of HCMV DNAemia due to the combination therapy
of baseline and augmented steroids. Once the patients
went from seronegative to seropositive and thus showed
HCMV reactivation, the peak viral load was similar in all
treatment groups regardless of steroid use. No difference
was observed in the incidence of DNAemia, this is probably
attributed to the very high incidence of HCMV in the
D+R2 group. This is clarified when assessing the indivi-
dual risk groups. In the absence of GCSs, HCMV
DNAemia was more prevalent in the D+R2 group such
that by day 30, 90% of D+R2 patients had experienced
DNAemia compared to 45% of the D+R+ group and
20% of the D2R+ group. The high incidence of
DNAemia in the D+R2 group precluded an assessment
of the impact of GCS; however, the other donor-recipient
serogroups were amenable for study. In the D2R+ group,
GCSs will only affect latent HCMV in the recipient.
Treatment of patients in the D2R+ group with both
baseline and augmented steroid therapy increased the
incidence of HCMV DNAemia. However, the limited
number of patients did not allow the study to reach
statistical significance (P50.07) at this point. In contrast,
in the D+R+ group, a significant increase in DNAemia
incidence was observed in the same treatment regimen. In
this group, GCSs can induce reactivation of latent HCMV
transferred with the transplanted organ in addition to
latent HCMV already present in the recipient. In the
Kaplan–Meier time to DNAemia curves, the combination
of both maintenance and augmented steroids led to both
the earlier detection of DNAemia and increased likelihood
of occurrence in the D+R+ group.
Taken together, the in vitro and clinical data presented here
strongly suggest the need to further investigate the influence
of GCSs on HCMV biology during in vitro and in vivo studies.
METHODS
Cell lines and primary cell types. ARPE-19 cells (CRL-2302;
ATCC) and neonatal NHDF fibroblasts (CC-2509; Lonza) were
propagated respectively in Dulbecco’s modified Eagle’s medium,
nutrient mixture F-12 (DMEM/F12) with L-glutamine (733-1713;
BioWhittaker) and Minimal essential medium (MEM), both contain-
ing 10% heat inactivated-FCS (HI-FCS) and 0.04% gentamicin. THP-
1 cells (TIB-202; ATCC) and THP-1-MIEP-EGFP (see below) were
grown in RPMI (Lonza) supplemented with 10% HI-FCS and 0.04%
gentamicin. HEK293 cells were cultured in DMEM (Lonza) containing
10% HI-FCS, 0.02 mg gentamicin ml21 and 1% L-glutamine.
Primary monocytes were differentiated to DCs, type 1 macrophages
and type 2 macrophages in X-Vivo-15 medium containing 2.5 mM
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L-glutamine supplemented with 100 ng GMCSF ml21 and 100 ng IL-
4 ml21, adapted from Hargett & Shenk (2010) and Verreck et al.
(2006), 100 ng GMCSF ml21 or 100 ng MCSF ml21, derived from
Verreck et al. (2006), respectively, for 7 days (all from Peprotech).
Viruses.High endothelial tropic stocks of the HCMV TB40/E (kindly
provided by C. Sinzger; Sinzger et al., 1999b), TB40/E-IE2-YFP
(Straschewski et al., 2010) and TB40/E-IE2-EGFP (kindly provided by
Professor Dr M. Winkler) strains were generated on ARPE-19 cells.
ARPE-19 cells were seeded in 175 cm2 flasks at 40–60% confluency
24 h prior to infection with TB40/E at m.o.i. 0.02 (3 h, room
temperature). The supernatant was collected until full cytopathic
effect. The supernatant of each harvest was spun down for 10 min at
600 g. The best six harvests were used for virus concentration by
centrifugation (1 h at 3000 g) and ultracentrifugation (1 h at 5800 g).
Ultracentrifuged virus was resuspended in medium and kept at
280 uC. The viral titre was determined by immunofluorescence
staining of the IE antigen [anti-I.E.A. (11-003); Argene and Alexa
Fluor 488 goat anti-mouse IgG (A-11001); Life Technologies].
MIEP-EGFP reporter THP-1 cell line. The MIEP of Merlin was
amplified using Phusion High Fidelity polymerase (New England
Biolabs) according to the manufacturer’s instructions using 0.3 mM
forward (TTCAAAATTTTATCGGATTTCTGTCGCCGACTAAATT-
CA) and reverse (CTGGACTAGTGGATCCGGTGTCTTCTATGGA-
GGTCA) primer. Subsequently, the HCMV promoter of pLenti6.3-
EGFP was removed by a ClaI/BamHI digest (Roche) and after vector
dephosphorylation (TSAP; Promega), the MIEP PCR fragment was
cloned in pLenti6.3-EGFP.
A stable cell line was established by lentiviral transduction. MIEP-
EGFP-lentivirus was prepared by seeding 26106 HEK293 cells in
15 cm2 Petri dishes. Two days later, the cells were triple lipo-
transfected with 5 mg pLenti-MIEP-EGFP, 5 mg GAG-pol packaging
plasmid and 2 mg VSVG envelope plasmid (lipofectamine; Life
Technologies). Twenty-four hours post-transfection, the medium
was replaced with 10 ml fresh medium supplemented with 1 mM
sodium butyrate. The next day, the medium was spun down at 600 g
for 10 min and stored at 280 uC. THP-1 cells were seeded and stably
transduced with the MIEP-EGFP lentiviral vector. The MIEP was
stimulated with 1 mM Pam3cys for 24 h after which the EGFP positive
cells were sorted using a FACS Aria cell sorter (BD). The cells were
incubated and grown for 2 weeks after transfection until the MIEP
was silenced again to background fluorescence.
THP-1-MIEP-EGFP reporter assay. The assay was validated to
ensure high robustness (Z950.91) (Zhang et al., 1999). In brief,
7.56104 cells were seeded in a 96-well plate in the presence of a
fourfold dilution series of a compound. Twenty-four hours after
compound addition, the percentage of EGFP expressing cells and the
MFI was read on a FACS Canto II. For each tested compound, the
lowest effective concentration (LEC) was determined i.e. the minimal
concentration needed to lift the restriction of the MIEP and to
produce a fluorescent signal three standard deviations above the
median of the background signal. In addition, the maximal response
(MaxResp) was determined i.e. the increase in signal compared to the
background where 100% increase equals a doubling in the percentage
of cells with an active MIEP.
shRNA against GR. shRNAs directed against the GR receptor (NR3C1
gene, TRCN0000245003-6), control genes LacZ (TRCN0000072225) and
Luc (TRCN0000072256), and the empty vector (TRCN0000208001)
were found on the RNAi Consortium shRNA Library website. Using
these sequences, the appropriate lentivirus was ordered (Sigma
Aldrich).
In brief, 105 shRNA transduced THP-1-MIEP-EGFP cells were
seeded in a 96-well plate. The MIEP was activated with 160 nM
prednisolone, 1 mM PMA or left quiescent (DMSO). Twenty-four
hours later, the percentage of EGFP expressing cells was determined
using a FACS Canto II (BD).
An average of all the negative control shRNAs was calculated and used
to normalize the other measurements and to calculate the fold
decrease. A two-tailed Student’s t-test was used to determine P values.
All P values below 0.001 were considered significant decreases of
MIEP activation.
The percentage of GR knockdown by the various shRNAs was
evaluated using RT-qPCR. THP-1-MIEP-EGFP cells transduced with
the shRNA were used to prepare RNA samples (RNeasy kit; Qiagen)
following the manufacturer’s instructions. cDNA was prepared using
Superscript-III reverse transcriptase (Life Technologies). RT-qPCR
analysis was performed using a qPCR core kit (Eurogentec) with
primer and probe sets for NR3C1 (GR receptor, Hs00353740_m1),
PGK1 (Phosphoglycerate kinase 1, Hs99999906_m1) and TFRC
(transferring receptor CD71, Hs00174609_m1) (Applied Biosystems)
according to the manufacturer’s instructions in an AB7900HT
Sequence analyser (Applied Biosystems).
Primary monocyte latency model. PBMCs and primary monocytes
were isolated from whole blood obtained via the Antwerp Blood
Transfusion Center.
In brief, 50 ml blood was diluted in 100 ml ice-cold PBS and applied
on 15 ml ficoll-paque layer. The PBMC fraction was separated by
centrifugation (800 g for 20 min, no brake), collected and washed
three times using ice-cold PBS. Monocytes were isolated using
magnetic CD14 microbeads (Miltenyi) as instructed by the
manufacturer. The monocytes were seeded at 105 cells per well
(96-well plate, tissue culture treated; Costar) and allowed to adhere
for 3 h at 37 uC and 5% CO2. After attachment, the PBS was
removed and 200 ml X-Vivo-15 medium (Lonza) was added. After
overnight incubation at 37 uC and 5% CO2, the cells were infected
with TB40/E-IE-YFP or TB40/E at m.o.i. 5 (3 h at room temperature
on a rocking platform). After infection, the virus was removed and
200 ml fresh X-Vivo 15 (2.5 mM L-glutamine) was added. The cells
were incubated for 3 days before adding compounds or before they
were differentiated. Fluorescent cells were counted manually after
96 h.
Treatment effects on cell count were tested while correcting for donor
dependency in a mixed model. Cell counts were log-transformed to
approach normality and pairwise comparisons were corrected for
multiple testing with the Tukey procedure. The mixed model analysis
was performed in SAS 9.2 (Littell et al., 2006).
Retrospective analysis of liver transplant patients. All liver
transplants (374 patients) performed and/or followed up at the Royal
Free Hospital, London, between July 2002 and the end of January
2010 were identified from the transplant database. All patients gave
their written informed consent for their laboratory results to be
analysed for research purposes. The studies and consent procedures
were approved by the Local Research Ethics Committee of the Royal
Free Hospital, London.
Patients were excluded if their HCMV serostatus, or that of their
donor, was unknown, if they had participated in the active arms of
other ongoing studies including an experimental HCMV vaccine
study reported elsewhere (Griffiths et al., 2011), if they had received
valganciclovir prophylaxis or if they received a multi-organ transplant.
Using these criteria, 321 liver recipients (108 females and 213 male, ages
19–83, mean age 48.9 years) were included in the analysis.
As baseline therapy in liver transplant patients, tacrolimus (Prograf;
Fujisawa) at 0.1 mg tacrolimus kg21 day21 was given nasogastrically
in two divided doses and started within 6 h after transplantation.
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Azathioprine was given intravenously and then orally (1 mg azathio
prine kg21 day21), and methylprednisolone (16 mg methylpredniso-
lone day21 intravenously) was given until oral intake was possible;
then, 20 mg prednisolone day21 was used. Tacrolimus dosing was
evaluated every other day and was adjusted with the goal of
maintaining a whole blood level between 5–10 ng tacrolimus ml21.
The azathioprine dose was not changed unless neutropenia developed.
Prednisolone was gradually tapered from 3 weeks and then stopped
between 3 and 6 months.
Acute cellular rejection episodes after liver transplantation were
managed with augmented steroid therapy using 1 g methylpredniso-
lone day21 for 3 days and repeated if rejection continued (up to a
maximum of 12 g in total) in addition to the baseline immuno-
suppression. If HCMV DNAemia was detected in a liver transplant
recipient, no changes in immunosuppressive therapy were undertaken
initially. However, depending on immunological risk (i.e. D+R2)
and/or high levels of HCMV load tacrolimus levels were reduced at
the discretion of the treating physician.
In the context of patients with baseline immunosuppressive steroid
and augmented immunosuppressive steroid data a total of 301
patients were available for analysis.
The HCMV IgG serostatus of all patients pre-transplant was
determined using the bioMe´rieux VIDAS assay until July 2008 after
which the Abbott Architect I2000 SR assay was used. Donor HCMV
IgG serostatus was determined using the same methods or, in the case
of donors from other hospitals, was provided by the National Health
Service British Transplant Service.
HCMV DNA in whole blood was quantified using a real-time PCR
approach described elsewhere (Atabani et al., 2012). HCMV
DNAemia was defined as detection of HCMV DNA in whole blood
above the assay cut-off (200 genomes ml21). Whole blood samples for
HCMV surveillance were collected twice a week while patients
remained in hospital and as out-patients for the first 60 days post-
transplant, then once a week with a targeted minimum follow-up of
the first 90 days after transplantation. Additional samples were
collected from HCMV viraemic patients to follow episodes through to
PCR-negativity. In patients with HCMV DNAemia surveillance
occurred over 149 days (range 5–415 days) and for those without
DNAemia, 94.9 days (range 0–247 days).
For comparisons of frequency of DNAemia Fisher’s exact test was
used. The time to onset of DNAemia (not normally distributed), the
medians were analysed in a Mann–Whitney test. Kaplan–Meier
survival analysis was performed to assess time to event (DNAemia
onset) in the different steroid subgroups. In all analysis a P value
¡0.05 was regarded as significant.
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